Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?
The biotech has been on a tear lately.
Overview
Moderna's (NASDAQ: MRNA) shares have already soared by 92% this year. Yet, the biotech is racing toward another catalyst. The company could receive an important regulatory approval on Aug. 5. Should investors purchase Moderna's shares before then?
Moderna developed mRNA-1010, an investigational flu vaccine. mRNA-1010 posted better efficacy numbers than some approved products in this category in phase 3 clinical trials. There is a large unmet need here, since the flu continues to cause thousands of hospitalizations every year, especially among older adults, the demographic Moderna is targeting with mRNA-1010.
Details
The U.S. Food and Drug Administration (FDA) set a PDUFA goal date -- or the target deadline by which it will either approve or reject Moderna's application for mRNA-1010 -- of Aug. 5.
Source
Originally published at www.fool.com.